National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Nab-paclitaxel (Abraxane®) in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinomoa of the pancreas.

Rapid Review

Commenced Completed Outcome
23/01/2014 02/03/2014 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
23/05/2014  05/09/2014 Reimbursement not recommended

The NCPE do not recommend reimbursement of nab-paclitaxel (Abraxane®).

Summary

 

December 2015

The HSE has approved reimbursement following confidential price negotiations.